Cantor Fitzgerald Reaffirms Neutral Rating for bluebird bio (NASDAQ:BLUE)

Cantor Fitzgerald restated their neutral rating on shares of bluebird bio (NASDAQ:BLUE) in a report issued on Monday, Benzinga reports.

A number of other equities research analysts have also recently commented on the stock. Bank of America lowered their price target on shares of bluebird bio from $4.00 to $3.00 and set a buy rating on the stock in a report on Thursday, August 15th. Robert W. Baird lowered their price target on shares of bluebird bio from $7.00 to $6.00 and set an outperform rating on the stock in a report on Thursday, August 15th. Barclays lowered their price target on shares of bluebird bio from $8.00 to $4.00 and set an overweight rating on the stock in a report on Thursday, August 15th. JPMorgan Chase & Co. cut shares of bluebird bio from an overweight rating to a neutral rating in a report on Thursday, August 15th. Finally, Royal Bank of Canada reissued a sector perform rating and set a $4.00 target price on shares of bluebird bio in a report on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Hold and an average target price of $4.74.

bluebird bio Trading Down 4.6 %

NASDAQ:BLUE opened at $0.58 on Monday. The stock has a market capitalization of $63.17 million, a PE ratio of -0.78 and a beta of 0.75. The firm’s 50 day moving average is $0.88 and its 200 day moving average is $1.01. bluebird bio has a 12 month low of $0.52 and a 12 month high of $5.53.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Allegheny Financial Group LTD bought a new position in shares of bluebird bio in the second quarter worth $25,000. Dynamic Technology Lab Private Ltd bought a new position in shares of bluebird bio in the fourth quarter worth $37,000. Enterprise Bank & Trust Co bought a new position in shares of bluebird bio in the first quarter worth $38,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of bluebird bio by 189.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 36,580 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 23,933 shares during the period. Finally, Sequoia Financial Advisors LLC increased its holdings in shares of bluebird bio by 48.0% in the first quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 13,000 shares during the period. Institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.